Show simple item record

FieldValueLanguage
dc.contributor.authorD'Emden, Michael C
dc.contributor.authorJenkins, Alicia J
dc.contributor.authorLi, Liping
dc.contributor.authorZannino, Diana
dc.contributor.authorMann, Kristy P
dc.contributor.authorBest, James D
dc.contributor.authorStuckey, Bronwyn GA
dc.contributor.authorPark, Kris
dc.contributor.authorSaltevo, Juha
dc.contributor.authorKeech, Anthony C
dc.date.accessioned2015-12-01
dc.date.available2015-12-01
dc.date.issued2014-08-23
dc.identifier.citationd'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC, on behalf of the FIELD Study Investigators. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2014; 57(11): 2296–2303.en_AU
dc.identifier.urihttp://hdl.handle.net/2123/14085
dc.description.abstractAims/hypothesis In the double-blind placebo-controlled Fenofibrate Intervention and Event Lowering in Diabetes trial (n=9795), fenofibrate reduced major cardiovascular events in type 2 diabetes. Sex-related differences in fenofibrate response could be clinically relevant and were pre-specified analyses. Methods Women (n=3657) and men (n= 6138) with type 2 diabetes not using statins were assigned fenofibrate (200 mg/day) or placebo for 5 years. Effects on lipoproteins and total cardiovascular events were evaluated by sex. Results Baseline total, LDL-, HDL- and non-HDL cholesterol and apolipoproteins A-I and B differed between sexes, and these and triacylglycerol levels improved with fenofibrate in both sexes (all p<0.001). Fenofibrate reduced total, LDL- and non-HDL cholesterol and apolipoprotein B more in women (all p<0.001), independent of menopausal status and statin uptake. Adjusted for covariates, fenofibrate reduced total cardiovascular outcomes (cardiovascular death, fatal and non-fatal stroke and carotid and coronary revascularisation) by 30% in women (95% CI 8%, 46%; p=0.008) and 13% in men (95% CI 5%, 61%; p=0.07) with no treatment-by-sex interaction (p>0.1). In patients with high triacylglycerol levels and low HDL-cholesterol, fenofibrate reduced total cardiovascular outcomes by 24% (95% CI 2%, 42%) in women and 30% (7%, 54%) in men, with no treatment-by-sex interaction (p>0.1). Conclusions/interpretation Fenofibrate improved the lipoprotein profile more in women than men. Cardiovascular event reductions with fenofibrate among women were consistently similar to men, including among those with low HDL-cholesterol and high triacylglycerol levels. These data provide reassurance about fenofibrate efficacy in women and men. Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection.en_AU
dc.language.isoenen_AU
dc.publisherSpringer-Verlagen_AU
dc.relationNHMRC grants 457103, 1024105 and 1037786en_AU
dc.subjectCardiovascular risken_AU
dc.subjectFibrateen_AU
dc.subjectClinical Trialen_AU
dc.subjectnon-insulin-dependent diabetes mellitusen_AU
dc.subjectstatinen_AU
dc.subjectsex differencesen_AU
dc.subjecttype 2 diabetesen_AU
dc.titleFavourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyen_AU
dc.typeArticleen_AU
dc.subject.asrcFoR::110306 - Endocrinologyen_AU
dc.type.pubtypePost-printen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.